 |
| |
| Nov-10-17 | Reiterated |
Stifel |
Buy |
$57 → $39 |
|
| Nov-10-17 | Reiterated |
Stifel |
Buy |
$39 → $57 |
|
| Dec-29-16 | Initiated |
Northland Capital |
Outperform |
$40 |
|
| May-03-16 | Initiated |
JMP Securities |
Mkt Outperform |
|
|
| Mar-01-16 | Reiterated |
Stifel |
Buy |
$69 → $57 |
|
| Mar-01-16 | Reiterated |
Mizuho |
Neutral |
$28 → $29 |
|
| Jan-25-16 | Reiterated |
Mizuho |
Neutral |
$42 → $28 |
|
| Nov-11-15 | Upgrade |
Mizuho |
Underperform → Neutral |
$45 → $42 |
|
| Oct-19-15 | Reiterated |
Wunderlich |
Buy |
$70 → $50 |
|
| Oct-14-15 | Initiated |
BofA/Merrill |
Neutral |
$35 |
|
| Sep-21-15 | Initiated |
Stifel |
Buy |
$69 |
|
| Aug-11-15 | Downgrade |
Mizuho |
Neutral → Underperform |
$45 |
|
| Aug-11-15 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Jul-27-15 | Reiterated |
Wunderlich |
Buy |
$55 → $70 |
|
| Jun-09-15 | Initiated |
Wunderlich |
Buy |
$55 |
|
| Mar-10-15 | Downgrade |
Mizuho |
Buy → Neutral |
$14 |
|
| Mar-03-15 | Reiterated |
Mizuho |
Buy |
$32 → $50 |
|
| Jan-23-15 | Reiterated |
Mizuho |
Buy |
$30 → $32 |
|
| Sep-03-13 | Initiated |
Mizuho |
Buy |
$30 |
|
| Sep-03-13 | Initiated |
Barclays |
Equal Weight |
$25 |
|
|
|
| Jun-20-18 08:00AM | Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Intrexon ACCESSWIRE |
| Jun-19-18 09:44AM | Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes PR Newswire |
| Jun-18-18 06:59PM | Cramer's lightning round: Medical device stocks tend to w... CNBC Videos |
| 06:48PM | Cramer's lightning round: Medical device stocks tend to win big CNBC |
| 07:30AM | Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy GlobeNewswire |
| Jun-11-18 04:12AM | Intrexon (XON) Down 9.2% Since Earnings Report: Can It Rebound? Zacks |
| Jun-04-18 07:56AM | Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire |
| May-31-18 10:26AM | Does Intrexon Corporations (NYSE:XON) Latest Financial Perfomance Look Strong? Simply Wall St. |
| May-29-18 08:00AM | Isolation and Recombinant Expression of Key Enzyme for Opioid Production PR Newswire |
| May-24-18 07:00AM | Oxitec Launches Field Trial in Brazil for Next Generation Addition to Friendly Mosquitoes Platform PR Newswire |
| May-23-18 08:11AM | The Cayman Government and Oxitec Launch Innovative Pilot to Suppress Aedes aegypti PR Newswire |
| May-21-18 08:00AM | Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001 PR Newswire |
| May-16-18 05:00PM | Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire |
| 07:45AM | Recent Analysis Shows H&R Block, Opko Health, Geron, Cardinal Health, Corning, and Intrexon Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
| May-14-18 08:00AM | Todays Research Reports on Stocks to Watch: Intrexon and Supernus Pharmaceuticals ACCESSWIRE |
| 08:00AM | Intrexon to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference PR Newswire |
| 07:10AM | Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks ACCESSWIRE |
| May-12-18 01:47AM | Edited Transcript of XON earnings conference call or presentation 10-May-18 9:30pm GMT Thomson Reuters StreetEvents |
| May-11-18 04:00PM | Here's What's Causing Intrexon to Tumble 20% Today Motley Fool -19.64% |
| 09:42AM | Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss Zacks |
| 08:30AM | Today's Research Reports on Trending Tickers: Intrexon Corporation and Synergy Pharmaceuticals ACCESSWIRE |
| May-10-18 04:05PM | Intrexon Announces First Quarter 2018 Financial Results PR Newswire |
| 04:01PM | Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire |
| May-08-18 04:45PM | AquaBounty Technologies, Inc. Results for the quarter ended March 31, 2018 GlobeNewswire |
| May-03-18 08:00AM | Intrexon to Announce First Quarter 2018 Financial Results on May 10th PR Newswire |
| May-02-18 10:54AM | What's in Store for Intrexon (XON) This Earnings Season? Zacks |
| 07:57AM | Ziopharm Oncology to Announce First Quarter 2018 Financial Results, Host Conference Call May 10 GlobeNewswire |
| Apr-27-18 11:15AM | AquaBounty Technologies, Inc. Announces FDA Approval of First U.S. Facility for Commercial Production of AquAdvantage Salmon GlobeNewswire |
| Apr-16-18 07:00AM | Exemplar Genetics Rare Neurological Disease Model Cleared by FDA for Commercial Research Use PR Newswire |
| Apr-13-18 11:43AM | Is Intrexon Corporation (NYSE:XON) As Strong As Its Balance Sheet Indicates? Simply Wall St. |
| Apr-06-18 08:19AM | Better Buy: Intrexon Corporation vs. Inovio Pharmaceuticals Inc. Motley Fool |
| Apr-03-18 08:20AM | Todays Research Reports on Trending Tickers: Intrexon and Portola Pharmaceuticals ACCESSWIRE +7.09% |
| Apr-02-18 04:11AM | Why Is Intrexon (XON) Up 18.8% Since Its Last Earnings Report? Zacks |
| Mar-29-18 09:25AM | ActoBio Therapeutics Greenlighted by FDA to Commence a Phase Ib/IIa Trial with AG019 for the Treatment of Early Onset Type 1 Diabetes PR Newswire |
| Mar-13-18 09:00AM | Newman Ferrara LLP Announces Corporate Governance Investigation of Intrexon Corporation - XON Business Wire |
| Mar-12-18 09:10AM | Todays Research Reports on Trending Tickers: Intrexon and Opko Health ACCESSWIRE |
| 09:00AM | Todays Research Reports on Trending Tickers: QEP Resources and Exxon Mobil ACCESSWIRE |
| Mar-08-18 04:30PM | AquaBounty Technologies, Inc. Results for the year ended December 31, 2017 GlobeNewswire |
| 07:40AM | Detailed Research: Economic Perspectives on Cardtronics, Helix Energy, Plains Group Holdings, Vista Outdoor, Intrexon, and Zimmer Biomet What Drives Growth in Today's Competitive Landscape GlobeNewswire |
| Mar-05-18 01:00PM | Dollar Tree Is One of 11 Stocks That Are Poised to Change Direction TheStreet.com |
| Mar-03-18 04:11PM | Edited Transcript of XON earnings conference call or presentation 1-Mar-18 10:30pm GMT Thomson Reuters StreetEvents |
| Mar-02-18 12:32PM | Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat Zacks +24.73% |
| Mar-01-18 04:05PM | Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results PR Newswire |
| 04:01PM | Ziopharm Oncology Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update GlobeNewswire |
| 01:30PM | Intrexon Corporation to Host Earnings Call ACCESSWIRE |
| 11:13AM | A Preview Of Intrexon's Q4 Earnings Benzinga |
| Feb-26-18 09:04PM | What's in Store for Intrexon (XON) This Earnings Season? Zacks |
| Feb-22-18 08:00AM | Intrexon to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1st PR Newswire |
| Feb-13-18 07:15AM | Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1 GlobeNewswire |
| Feb-12-18 07:00AM | Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond GlobeNewswire |
| Feb-06-18 10:22AM | See the D.C.-area stocks hit hardest in the last week American City Business Journals +8.41% |
| 08:55AM | Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance GlobeNewswire |
| Feb-01-18 08:20AM | Todays Research Reports on Trending Tickers: Incyte Corporation and Intrexon Corporation ACCESSWIRE |
| Jan-30-18 08:00AM | Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) GlobeNewswire -5.68% |
| Jan-29-18 05:39PM | First Eagle Fund of America 4th Quarter Commentary GuruFocus.com |
| 09:57AM | Weekly CEO Buys Highlight GuruFocus.com |
| Jan-28-18 03:18PM | Better Buy: Intrexon Corporation vs. Celgene Motley Fool |
| Jan-19-18 04:34PM | Why IBM, GNC Holdings, and Intrexon Slumped Today Motley Fool |
| 10:41AM | Intrexon Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters PR Newswire |
| Jan-17-18 09:16AM | Intrexon Prices Public Offering of Common Stock PR Newswire |
| Jan-16-18 04:15PM | Intrexon Announces Proposed Public Offering of Common Stock PR Newswire -6.39% |
| Jan-12-18 09:20AM | AquaBounty Technologies, Inc. Announces $12 Million Underwritten Public Offering GlobeNewswire +11.27% |
| 08:05AM | See what the IHS Markit Score report has to say about Intrexon Corp. Markit |
| Jan-10-18 08:05AM | See what the IHS Markit Score report has to say about Intrexon Corp. Markit |
| Jan-09-18 07:00AM | Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire +7.55% |
| Jan-04-18 08:35AM | Intrexon's ActoBio Therapeutics to Present at Biotech Showcase 2018 on January 8 PR Newswire -8.45% |
| 08:30AM | Intrexon to Present at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire |
| Jan-03-18 03:52PM | A Cash Infusion From the Boss Props Up Intrexon -- For Now Barrons.com |
| Jan-02-18 08:00AM | Intrexon Corporation Annual CEO Letter PR Newswire +16.93% |
| Dec-27-17 12:06PM | ETFs with exposure to Intrexon Corp. : December 27, 2017 Capital Cube |
| Dec-26-17 08:55AM | Intrexon Corp. :XON-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017 Capital Cube |
| Dec-21-17 04:05PM | ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire |
| Dec-14-17 02:18PM | ETFs with exposure to Intrexon Corp. : December 14, 2017 Capital Cube -6.44% |
| Dec-06-17 08:43AM | Why Intrexon (XON) Could Be Positioned for a Slump Zacks |
| Nov-28-17 08:06AM | Intrexon Corporation (XON)s Earnings Grew 24.8%, Is It Enough? Simply Wall St. |
| 08:04AM | See what the IHS Markit Score report has to say about Intrexon Corp. Markit |
| Nov-27-17 08:20AM | Report: Developing Opportunities within Social Reality, The Finish Line, Facebook, Organovo, Plug Power, and Intrexon Future Expectations, Projections Moving into 2018 GlobeNewswire |
| 08:00AM | Intrexon Announces Key Management Appointments PR Newswire |
| Nov-26-17 07:21AM | Edited Transcript of XON earnings conference call or presentation 9-Nov-17 10:30pm GMT Thomson Reuters StreetEvents |
| Nov-22-17 08:03AM | See what the IHS Markit Score report has to say about Intrexon Corp. Markit +7.84% |
| Nov-20-17 07:00AM | ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting GlobeNewswire |
| Nov-17-17 08:00AM | Todays Research Reports on Trending Tickers: Egalet Corporation and Intrexon Corporation ACCESSWIRE -5.65% |
| 07:00AM | ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology GlobeNewswire |
| Nov-16-17 07:00AM | AquaBounty wins Gold Leaf Award for Best Emerging Agriculture Company from BIOTECanada GlobeNewswire +7.67% |
| 05:54AM | Bill Miller, Kris Jenner share stocks they've got their eye on American City Business Journals |
| Nov-15-17 08:20AM | Todays Research Reports on Trending Tickers: Array BioPharma and Intrexon Corporation ACCESSWIRE |
| 08:05AM | Here's What You Need to Know About Intrexon's Third-Quarter 2017 Earnings Motley Fool |
| 07:30AM | Featured Company News - Zymeworks Enters Into License Agreement with Janssen Biotech to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics ACCESSWIRE |
| Nov-14-17 08:55AM | Intrexon (XON) in Focus: Stock Moves 6.5% Higher Zacks |
| Nov-12-17 07:00PM | Is Peak Permian Only 3 Years Away? Oilprice.com |
| Nov-10-17 05:40PM | Why Intrexon Corporation Stock Got Crushed Today Motley Fool -25.63% |
| 04:05PM | ZIOPHARM to Present at the Stifel 2017 Healthcare Conference GlobeNewswire |
| 08:49AM | Intrexon (XON) Q3 Loss Narrower Than Expected, Revenues Miss Zacks |
| 08:00AM | Intrexon to Present at the Stifel 2017 Healthcare Conference PR Newswire |
| Nov-09-17 04:05PM | Intrexon Announces Third Quarter 2017 Financial Results PR Newswire |
| 03:00PM | Intrexon Corporation to Host Earnings Call ACCESSWIRE |
| 08:35AM | Why Intrexon Corporation (XON) Could Be A Buy Simply Wall St. |
| Nov-08-17 08:16AM | Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND Zacks |
| Nov-06-17 04:05PM | ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities GlobeNewswire |
| 07:00AM | ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology GlobeNewswire |
|
|
|
|
| Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms. The company also provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. It serves health, food, energy, environment, and consumer markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Ares Trading S.A.; Intrexon Energy Partners II, LLC; Intrexon T1D Partners, LLC; AquaBounty Technologies, Inc.; Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| ALVAREZ CESAR L | Director | Feb 20 | Option Exercise | 2.64 | 8,906 | 23,512 | 114,849 | Feb 22 04:51 PM | | Frank Steven | Director | Feb 12 | Option Exercise | 2.64 | 8,906 | 23,512 | 189,093 | Feb 14 08:06 PM | | KIRK RANDAL J | Chief Executive Officer | Jan 19 | Buy | 12.50 | 1,000,000 | 12,500,000 | 7,782,622 | Jan 22 09:04 AM | | KIRK RANDAL J | 10% Owner | Dec 11 | Buy | 0.77 | 2,727,273 | 2,100,000 | 5,773,626 | Dec 13 05:28 PM | | Last Andrew J. | Chief Operating Officer | Nov 13 | Buy | 12.10 | 2,000 | 24,200 | 4,000 | Nov 15 04:17 PM | | Reed Thomas D. | Chief Science Officer | Oct 16 | Option Exercise | 2.64 | 38,598 | 101,899 | 102,715 | Oct 17 04:59 PM | | Gupta Vinita D | Director | Aug 22 | Buy | 17.61 | 3,000 | 52,830 | 3,000 | Aug 23 04:37 PM | | SHAPIRO ROBERT B | Director | Aug 22 | Buy | 17.50 | 2,850 | 49,883 | 82,966 | Aug 23 04:34 PM | | Last Andrew J. | Chief Operating Officer | Aug 14 | Buy | 19.99 | 2,000 | 39,980 | 2,000 | Aug 15 01:14 PM | | KINDLER JEFFREY B | Director | Aug 11 | Buy | 18.32 | 5,440 | 99,661 | 71,762 | Aug 15 01:15 PM | | Nimrodi Nir | SVP-Corporate Development | Aug 11 | Buy | 18.75 | 3,369 | 63,169 | 7,369 | Aug 14 08:33 AM | | Lehr Donald P. | Chief Legal Officer | Aug 11 | Buy | 18.33 | 1,094 | 20,053 | 28,249 | Aug 11 01:08 PM | | Perez Jeffrey Thomas | SVP, IP Affairs | Aug 11 | Buy | 17.89 | 1,000 | 17,890 | 12,537 | Aug 11 01:04 PM | | MITCHELL DEAN J | Director | Aug 11 | Buy | 18.33 | 5,000 | 91,640 | 18,103 | Aug 11 01:03 PM | | KIRK RANDAL J | Chief Executive Officer | Aug 11 | Buy | 18.85 | 132,625 | 2,499,981 | 6,782,622 | Aug 14 08:57 AM | | Sterling Rick L. | Chief Financial Officer | Jul 07 | Option Exercise | 2.64 | 68,252 | 180,185 | 74,621 | Jul 10 08:32 AM |
|
|
|
|
|
|
